BioSpace News Archive

ABVC Biopharma, Inc. today announced the enrollment progress in the Phase II Part II clinical study of the Company’s ADHD medicine (ABV-1505).

South Korean Ministry of Food and Drug Safety granted IND approval for a clinical phase 1/2a trial to evaluate safety and efficacy of RZNOMICS lead gene therapy RZ001 for the treatment of primary liver cancer.

Urban Poling Inc. is pleased to announce that Urban Poling ACTIVATOR poles have received the Arthritis Foundation’s Ease of Use Certification.

Novartis Pharmaceuticals Corporation to collaborate on development of new medical device software for earlier detection and intervention in cardiovascular disease.

Endevica Bio, a company developing first-in-class peptide drug candidates with better safety and efficacy properties, announced the first patient in its Phase 1 study has been dosed with TCMCB07, the company’s melanocortin‐4 antagonist peptide candidate for the treatment of cachexia.

GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced completion of sample collection and analysis of glucose in oral fluid and blood samples from their clinical study at the Diabetes Research Institute of Sutter Health’s Mills-Peninsula Medical Center (MPMC) in San Mateo, California.

Intratech Medical, developer of the Booster™ spiral balloon therapy for the treatment of AMI patients, announced the successful enrollment of two patients in a multi-center first in human study to assess the safety and technical performance of their Booster balloon in the treatment of patients undergoing coronary catheterization.

Sports Data Labs, Inc. (“SD Labs”), announced today that the United States Patent and Trademark Office has issued U.S. Patent No. 11,382,510 to the company covering a novel remote health monitoring and biofeedback system operable for real-time, two-way, direct communication with sensors and sensing systems via the use of a browser-based web application.

Q-State Biosciences (“Q-State”), a discovery technology and therapeutics company advancing programs for the treatment of serious central nervous system disorders, announced today the publication of a peer reviewed original research article in Frontiers in Molecular Neuroscience.

Navitus Health Solutions, an industry-disrupting pharmacy benefit manager (PBM) committed to bringing humanity to pharmacy benefits management through greater transparency and affordability, and CivicaScript,TM a statutory public benefit company dedicated to bringing lower-cost generic medicines to U.S. consumers, announced today that Navitus has joined CivicaScript as a founding member.